Claim: Redatide, developed by Eli Lilly, impacts the GLP, GIP, and glucagon systems and leads to the most robust weight loss among GLP peptides.
Verdict: Partially True (80% confidence)
Explanation: According to PMC, retatrutide is developed by Eli Lilly and impacts the GLP, GIP, and glucagon systems, leading to significant weight loss (PMC). UCHealth reports that retatrutide helped people lose 30% of their body weight, which is a robust result (UCHealth). However, no source explicitly states that retatrutide leads to the most robust weight loss among all GLP peptides, leaving this part of the claim unverified.